Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay characteristics and the HIV viral reservoir

No abstract is available for this paper.

• Publication year

  2011

• Venue

  AIDS (London)

• Publication date

  2011-11-13

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/QAD.0b013e32834b9658PMID 21860347
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication.

  2011cited by this paper
• HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects

  2010cited by this paper
• Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy.

  2010cited by this paper
• Profound Depletion of HIV-1 Transcription in Patients Initiating Antiretroviral Therapy during Acute Infection

  2010cited by this paper
• HIV–1 Infects Multipotent Progenitor Cells Causing Cell Death and Establishing Latent Cellular Reservoirs

  2010cited by this paper
• Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication

  2010cited by this paper
• Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy.

  2010cited by this paper
• The Effect of Raltegravir Intensification on Low-level Residual Viremia in HIV-Infected Patients on Antiretroviral Therapy: A Randomized Controlled Trial

  2010cited by this paper
• HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation

  2009cited by this paper
• The Challenge of Finding a Cure for HIV Infection

  2009cited by this paper
• Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy

  2009cited by this paper
• Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy

  2008cited by this paper
• Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy.

  2008cited by this paper
• HIV rebounds from latently infected cells, rather than from continuing low-level replication

  2008cited by this paper
• Rapid and Durable Antiretroviral Effect of the HIV-1 Integrase Inhibitor Raltegravir as Part of Combination Therapy in Treatment-Naive Patients With HIV-1 Infection: Results of a 48-Week Controlled Study

  2007cited by this paper
• Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase

  2007cited by this paper
• ART Suppresses Plasma HIV-1 RNA to a Stable Set Point Predicted by Pretherapy Viremia

  2007cited by this paper
• Residual Human Immunodeficiency Virus Type 1 Viremia in Some Patients on Antiretroviral Therapy Is Dominated by a Small Number of Invariant Clones Rarely Found in Circulating CD4+ T Cells

  2006cited by this paper
• Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1.

  2005cited by this paper
• In Vivo Evidence for Instability of Episomal Human Immunodeficiency Virus Type 1 cDNA

  2005cited by this paper
• Azido-Containing Diketo Acid Derivatives Inhibit Human Immunodeficiency Virus Type 1 Integrase In Vivo and Influence the Frequency of Deletions at Two-Long-Terminal-Repeat-Circle Junctions

  2004cited by this paper
• Continued Production of Drug-Sensitive Human Immunodeficiency Virus Type 1 in Children on Combination Antiretroviral Therapy Who Have Undetectable Viral Loads

  2004cited by this paper
• Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells

  2003cited by this paper
• New Real-Time Reverse Transcriptase-Initiated PCR Assay with Single-Copy Sensitivity for Human Immunodeficiency Virus Type 1 RNA in Plasma

  2003cited by this paper
• Longitudinal monitoring of 2-long terminal repeat circles in peripheral blood mononuclear cells from patients with chronic HIV-1 infection

  2003cited by this paper
• Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination.

  2002cited by this paper
• Human Immunodeficiency Virus cDNA Metabolism: Notable Stability of Two-Long Terminal Repeat Circles

  2002cited by this paper
• Intrinsic Stability of Episomal Circles Formed during Human Immunodeficiency Virus Type 1 Replication

  2002cited by this paper
• HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy.

  2001cited by this paper
• Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy

  2000cited by this paper
• Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells.

  2000cited by this paper
• Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy.

  1999cited by this paper
• HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression.

  1999cited by this paper
• Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection.

  1998cited by this paper
• Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy.

  1997cited by this paper
• Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.

  1997cited by this paper
• Recovery of replication-competent HIV despite prolonged suppression of plasma viremia.

  1997cited by this paper

• Impact of antiretroviral therapy during acute or early HIV infection on virologic and immunologic outcomes: results from a multinational clinical trial

  2024cites this paper
• Antigen specificities and proviral integration sites differ in HIV-infected cells by timing of antiretroviral treatment initiation

  2024cites this paper
• Assessing advances in three decades of clinical antiretroviral therapy on the HIV-1 reservoir

  2024cites this paper
• The build-up of stock of stable integrated proviruses overtime explains the difficulty in reducing HIV-1 DNA levels when treatment is initiated at the chronic stage of the infection

  2023cites this paper
• Genotypic Resistance Testing of HIV-1 DNA in Peripheral Blood Mononuclear Cells

  2022cites this paper
• Raltegravir Inclusion Decreases CD4 T-Cells Intra-Cellular Viral Load and Increases CD4 and CD28 Positive T-Cells in Selected HIV Patients

  2022cites this paper
• Serum globulin levels are associated with HIV reservoir size and immune restoration during long‐term ART

  2022cites this paper
• Long-term effects of early antiretroviral initiation on HIV reservoir markers: a longitudinal analysis of the MERLIN clinical study

  2021cites this paper
• Preservation of Gastrointestinal Mucosal Barrier Function and Microbiome in Patients With Controlled HIV Infection

  2021cites this paper
• CD73+ CD127high Long-Term Memory CD4 T Cells Are Highly Proliferative in Response to Recall Antigens and Are Early Targets in HIV-1 Infection

  2021cites this paper
• Initiation of Antiretroviral Therapy during Primary HIV Infection: Effects on the Latent HIV Reservoir, Including on Analytic Treatment Interruptions.

  2020cites this paper
• Mapping the extent of heterogeneity of human CCR5+ CD4 T-cells in peripheral blood and lymph nodes.

  2020cites this paper
• HIV-1 DNA decay dynamics in early treated individuals: practical considerations for clinical trial design

  2020cites this paper
• Impact of Raltegravir or Efavirenz on Cell-Associated Human Immunodeficiency Virus-1 (HIV-1) Deoxyribonucleic Acid and Systemic Inflammation in HIV-1/Tuberculosis Coinfected Adults Initiating Antiretroviral Therapy

  2020cites this paper
• Establishment of latent HIV-1 reservoirs: what do we really know?

  2019cites this paper
• Development of an Ultrasensitive HIV-1 DNA Detection Assay Based on an Automated πCode End-Point PCR System

  2019cites this paper
• Possible clearance of transfusion-acquired nef/LTR-deleted attenuated HIV-1 infection by an elite controller with CCR5 Δ32 heterozygous and HLA-B57 genotype

  2019cites this paper
• The effects of antiretroviral therapy initiation time on HIV reservoir size in Chinese chronically HIV infected patients: a prospective, multi-site cohort study

  2019cites this paper
• Increasing contribution of integrated forms to total HIV DNA in blood during HIV disease progression from primary infection

  2019cites this paper
• HIV-1 DNA Is Maintained in Antigen-Specific CD4+ T Cell Subsets in Patients on Long-Term Antiretroviral Therapy Regardless of Recurrent Antigen Exposure

  2019cites this paper
• Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection

  2018cites this paper
• Measuring integrated HIV DNA ex vivo and in vitro provides insights about how reservoirs are formed and maintained

  2018cites this paper
• RNA-induced epigenetic silencing inhibits HIV-1 reactivation from latency

  2018cites this paper
• Immunovirological outcome and HIV-1 DNA decay in a small cohort of HIV-1-infected patients deintensificated from Abacavir/Lamivudine/Dolutegravir to Lamivudine plus Dolutegravir.

  2018cites this paper
• Impact des inhibiteurs de l'intégrase sur la constitution et la compartimentalisation du réservoir viral

  2018cites this paper
• HIV dynamics linked to memory CD4+ T cell homeostasis

  2017cites this paper
• Quantification of Residual Germinal Center Activity and HIV-1 DNA and RNA Levels Using Fine Needle Biopsies of Lymph Nodes During Antiretroviral Therapy

  2017cites this paper
• HIV infection is influenced by dynamin at 3 independent points in the viral life cycle

  2017cites this paper
• Time course of cellular HIV-DNA and low-level HIV viremia in HIV–HCV co-infected patients whose HCV infection had been successfully treated with directly acting antivirals

  2017cites this paper
• The investigation of CD4+T-cell functions in primary HIV infection with antiretroviral therapy

  2017cites this paper
• Utility of integrated HIV-1 DNA quantification in cure studies

  2017cites this paper
• Impact of Different Antiretroviral Strategies on Total HIV-DNA Level in Virologically Suppressed HIV-1 Infected Patients

  2017cites this paper
• Dasatinib inhibits HIV-1 replication through the interference of SAMHD1 phosphorylation in CD4+ T cells.

  2016cites this paper
• HIV‐1 DNA dynamics and variations in HIV‐1 DNA protease and reverse transcriptase sequences in multidrug‐resistant patients during successful raltegravir‐based therapy

  2016cites this paper
• Achieving HIV-1 Control through RNA-Directed Gene Regulation

  2016cites this paper
• Total HIV-1 DNA, a Marker of Viral Reservoir Dynamics with Clinical Implications

  2016cites this paper
• A Pilot Study of Raltegravir Plus Combination Antiretroviral Therapy in Early Human Immunodeficiency Virus Infection: Challenges and Lessons Learned

  2016cites this paper
• Novel Assays for Measurement of Total Cell-Associated HIV-1 DNA and RNA

  2016cites this paper
• Investigating the feasibility of incorporating Vpx into lentiviral gene therapy vectors: at a global and targeted scale

  2016cites this paper
• Monitoring Integration over Time Supports a Role for Cytotoxic T Lymphocytes and Ongoing Replication as Determinants of Reservoir Size

  2016cites this paper
• CD4+ T Follicular Helper and IgA+ B Cell Numbers in Gut Biopsies from HIV-Infected Subjects on Antiretroviral Therapy Are Similar to HIV-Uninfected Individuals

  2016cites this paper
• Correction: HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days—Implications for HIV Remission

  2016cites this paper
• HIV Replication at Low Copy Number and its Correlation with the HIV Reservoir: A Clinical Perspective

  2015cites this paper
• Evaluation of the effect of short-term treatment with the integrase inhibitor raltegravir (Isentress) on the course of progressive feline leukemia virus infection.

  2015cites this paper
• HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days—Implications for HIV Remission

  2015cites this paper
• HIV-Infected Spleens Present Altered Follicular Helper T Cell (Tfh) Subsets and Skewed B Cell Maturation

  2015cites this paper
• How does the timing of antiretroviral therapy initiation in acute infection affect HIV reservoirs?

  2015cites this paper
• The HIV treatment cascade in acutely infected people: informing global guidelines

  2015cites this paper
• Dynamics of HIV DNA and residual viremia in patients treated with a raltegravir-containing regimen.

  2015cites this paper
• Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial.

  2015cites this paper
• Impact of Antiretroviral Therapy on HIV-1 Persistence: The Case for Early Initiation.

  2015cites this paper
• Early antiretroviral therapy with raltegravir generates sustained reductions in HIV reservoirs but not lower T-cell activation levels

  2015cites this paper
• Controlling HIV-1: Non-Coding RNA Gene Therapy Approaches to a Functional Cure

  2015cites this paper
• Immunological and pharmacological strategies to reactivate HIV-1 from latently infected cells: a possibility for HIV-1 paediatric patients?

  2015cites this paper
• Changes in HIV reservoirs during long-term antiretroviral therapy

  2015cites this paper
• Novel RNA Duplex Locks HIV-1 in a Latent State via Chromatin-mediated Transcriptional Silencing

  2015cites this paper
• The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo

  2015cites this paper
• [Key role played by the gut associated lymphoid tissue during human immunodeficiency virus infection].

  2015cites this paper
• Measuring Turnover of SIV DNA in Resting CD4+ T Cells Using Pyrosequencing: Implications for the Timing of HIV Eradication Therapies

  2014cites this paper
• Promoter targeted small RNAs: stabilising viral reservoirs

  2014cites this paper
• Impact of raltegravir on HIV-1 RNA and DNA forms following initiation of antiretroviral therapy in treatment-naive patients.

  2014cites this paper
• Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection

  2014cites this paper
• HIV DNA Subspecies Persist in both Activated and Resting Memory CD4+ T Cells during Antiretroviral Therapy

  2014cites this paper
• The Majority of HIV Type 1 DNA in Circulating CD4+ T Lymphocytes Is Present in Non-Gut-Homing Resting Memory CD4+ T Cells

  2013cites this paper
• An HIV-1 Replication Pathway Utilizing Reverse Transcription Products That Fail To Integrate

  2013cites this paper
• UvA-DARE ( Digital Academic Repository ) Treatment of primary HIV infection

  2013cites this paper
• Treatment of primary HIV infection

  2013cites this paper
• Dynamics of the HIV-1 latent reservoir after discontinuation of the intensification of antiretroviral treatment: results of two clinical trials

  2013cites this paper
• Short communication: HIV blips while on antiretroviral therapy can indicate consistently detectable viral levels due to assay underreporting.

  2013cites this paper
• Innate and Adaptive Immunity in Long-Term Non-Progression in HIV Disease

  2013cites this paper
• Quantitation of integrated proviral DNA in viral reservoirs

  2013cites this paper
• The search for an HIV cure: tackling latent infection.

  2013cites this paper
• Impact of the DNA extraction method on 2-LTR DNA circle recovery from HIV-1 infected cells.

  2013cites this paper
• The use of HIV-1 integrase inhibitors in antiretroviral naive patients

  2012cites this paper
• Similar virologic response after initiation of triple-class antiretroviral therapy in primary and chronic HIV infection.

  2012cites this paper
• The effect of intensification with raltegravir on the HIV-1 reservoir of latently infected memory CD4 T cells in suppressed patients

  2012cites this paper
• Switching Virally Suppressed, Treatment-Experienced Patients to a Raltegravir-Containing Regimen Does Not Alter Levels of HIV-1 DNA

  2012cites this paper
• Integrated HIV DNA accumulates prior to treatment while episomal HIV DNA records ongoing transmission afterwards

  2012cites this paper